Currently incurable, peripheral neuropathies are common neurological complications of chemotherapy, causing persistent pain, tingling and burning sensations in the feet and hands, sometimes even after treatment has ended. In the hope of offering a therapeutic option to affected patients, a research team led by a CNRS researcher has identified a molecule capable of preventing the onset of such side effects.
This molecule stimulates the production of a compound essential for cellular energy production, on which the survival of all our cells depends, and promotes the resilience of nerve cells to damage caused by chemotherapy treatments, such as paclitaxel. This mechanism is described in a study published in Science Advances.
Tested on cell cultures and on rodents, this newly discovered molecule has been shown to limit the degradation of nerve cells usually affected in the extremities, thereby reducing painful symptoms without altering the anti-tumor action.
At a time when chemotherapy-related neuropathies affect 80% of patients and persist in nearly a quarter of them—often forcing a reduction in cancer treatment—this discovery offers real hope. Within a few years, the molecule will undergo clinical trials, the first step towards possible therapeutic application, once the regulatory preclinical stages have been validated.
More information:
Lauriane Bosc et al, Preventing neuropathy and improving anticancer chemotherapy with a carbazole-based compound, Science Advances (2025). DOI: 10.1126/sciadv.adw6328
The content is provided for information purposes only.